d o i : 1 0 . 1 1 1 1 / j . 1 3 6 8 - 5 0 3 1 . 2 0 0 5 . 0 0 4 9 2 . x
The participation of health professionals in a smoking-cessationprogramme positively influences the smoking cessation advicegiven to patients
P . M . J . P U S K A , 1 M . B A R R U E C O , 2 C . R O U S S O S , 3 A . H I D E R , 4 S . H O G U E 5National Public Health Institute,1 Helsinki, Finland, Salamanca University,2 Salamanca, Spain, Evangelismos General Hospital,3Athens, Greece, GlaxoSmithKline Research and Development,4 Greenford, Middlesex, UK, GlaxoSmithKline Research andDevelopment,5 Research Triangle Park, NC, USA
study participants became more proactive with their smok-
ing cessation advice. A positive shift from baseline to end
This study assessed the degree of smoking cessation advice
of study was observed with respect to the advice and
given by health professionals, before and after their parti-
support they gave to their smoking patients. These changes
cipation in a smoking cessation study using bupropion-
were not related to study treatment or current smoking
sustained release (bupropion SR, ZybanÒ). A total of 690
status. An increase in advising patients to quit smoking and
physicians and nurses who had smoked an average of 10
in offering cessation counselling was observed. Participa-
cigarettes/day over the previous year and were motivated to
tion in a smoking-cessation study by physicians and nurses
quit smoking, were randomised in a double-blind manner
who smoke has a positive effect, regardless of study med-
to receive bupropion SR (days 1–3, 150 mg/day; days
ication, in smoking cessation advice and counselling given
4–49, 150 mg twice daily) or placebo for 7 weeks, with
follow-up to week 52. All subjects received regular follow-
Keywords: Smoking; cessation; attitudes; support; physi-
up and brief motivational support throughout the study.
Questions regarding their smoking cessation advice formedpart of the study, with the aim of determining whether
(5,6). Smoking among nurses also tends to be high, with rates
up to 40% in countries such as Northern Ireland and Italy (7,8).
Tobacco smoking is one of the most significant causes of
Nardini et al. have previously reported that physicians who
morbidity and mortality in modern society. Approximately
smoke tend to underestimate the health hazards associated
half of all continuing smokers die from smoking-related dis-
with smoking compared with their nonsmoking counterparts
eases, with an average loss of 20–25 years life expectancy per
(9). A review of the literature suggests that health profes-
smoker (1). Smoking causes the majority of lung cancers,
sionals who smoke may not be as effective in counselling
accounting for approximately 30% of all cancer deaths (2).
patients to quit smoking as health professionals who do not
Similarly, 30% of deaths because of cardiovascular diseases are
smoke (10). Physicians who regularly smoke tend to convey a
as a result of smoking (3). Many smokers wish to give up their
more negative attitude towards smoking-cessation interven-
smoking because of these health risks.
tion, and they often downplay their role in highlighting the
As an aid to successful smoking cessation, the help and advice
health risks associated with smoking (11,12). Also, physicians
of health professionals such as doctors and nurses is important
who smoke do not recognise that they should set an example
(4). However, many health professionals continue to smoke,
as a positive role model to patients (13).
despite the health risks involved. According to recent World
The interaction of health professionals with their patients
Health Organization (WHO) figures, smoking rates among
who smoke, therefore, appears to be a relevant factor in the
physicians vary considerably; 4–5% of physicians in the UK
success of their patients’ attempts to stop smoking. Indeed,
regularly smoke compared with 34% in Italy and France,
many studies have shown that health professionals have an
whereas in countries such as Spain the rate may exceed 50%
important role to play in reducing smoking prevalence and ininfluencing smoking cessation. For example, the Agency forHealth Care Policy and Research has given smoking-cessationcounselling from physicians its highest recommendation (14).
Smokers have been shown to cite a physician’s advice to quit
Pekka Puska, MD, PhD, MPolSc, National Public Health Institute
as an important motivator for attempting to stop smoking
(KTL), Mannerheimintie 166, FIN 00300 Helsinki, FinlandEmail: [email protected]
(15), and the WHO has stated that health professionals
ª 2005 Blackwell Publishing Ltd Int J Clin Pract, April 2005, 59, 4, 447–452
CHANGING HEALTH PROFESSIONALS’ ATTITUDES TO SMOKING
should be involved in an active and exemplary way in quitting
smoking (5). It has been suggested that if smoking prevalence
This was a multicentre, randomised, double-blind, placebo-
amongst physicians fell below that of the general population,
controlled study conducted at 26 centres across 12 countries.
in a few decades the smoking prevalence among the general
The majority of the study centres were from the secondary
population would also decrease (16).
care setting. The study was approved by the investigational
The present study assessed the degree of smoking cessation
centre ethics committee or the Institutional Review Board of
advice given by health professionals (defined as qualified
the participating centres and was performed in accordance
physicians and nurses), before and after participation in a
with the Declaration of Helsinki, June 1964, as modified by
study of smoking cessation using bupropion-sustained release
the 48th World Medical Association, Republic of South
(bupropion SR, ZybanÒ), the first non–nicotine-based pharma-
Africa, October 1996. Written informed consent was
cological aid to smoking cessation. Bupropion SR has been
obtained from all study participants prior to entry into the
shown to be an effective aid to smoking cessation in clinical
studies (17,18), which has been acknowledged in smoking
The study consisted of a 1–2-week screening/baseline
cessation guidelines (19–21). The smoking cessation results
phase, a 7-week treatment phase and follow-up at 12, 26
from the current study are presented elsewhere and showed
and 52 weeks. Regardless of treatment assignment, all patients
higher quit rates with bupropion SR as compared with pla-
received brief motivation support (approximately 10 min)
cebo with statistical differences through the treatment phase (22).
provided by trained counsellors either in person or byphone, weekly during the treatment phase and monthly dur-
ing the follow-up phase. This report represents the analysis ofthe answers to questions regarding advice given to smoking
patients by these health professionals (Table 1). The responses
Subjects in the study were healthcare professionals (defined as a
to questions were either dichotomous or Likert type as iden-
practising physician or nurse), aged 18 years of age, who had
tified in Table 1. The questions were included in the study
smoked on average 10 cigarettes per day during the previous
after assessment of content validity by experts in the field. The
year and who had not made a serious attempt (lasting > 3
questions were completed during the study at baseline, week 7
months) to stop smoking during this period. All participants
(end of treatment) and week 52 or at premature discontinua-
were motivated to quit smoking and were free from significant
tion. The number of participants completing each question
cardiac, pulmonary, gastrointestinal, hepatic, renal, haemato-
varied, as not all questions were applicable to each subject
logical, neurological and psychiatric disease.
depending on their professional degree and the nature of their
Subjects were excluded if they had experienced seizures pre-
viously or were predisposed to seizures, had a current diagnosisof severe cardiac, pulmonary, hepatic, renal, haematological or
neurological disease or had a history or current diagnosis ofbulimia, anorexia nervosa, panic disorder, psychosis or bipolar
For the purpose of this subanalysis, the main outcome was the
disorder or were depressed. Participants were also ineligible
assessment of the responses to the smoking advice questions.
if they had uncontrolled hypertension, had used nicotine-
Primary analyses were performed on the population of partici-
replacement therapy for a serious quit attempt during the
pants who completed a questionnaire at baseline and at week 52.
previous 3 months, had previously used bupropion SR for
smoking cessation or were using other treatments for smoking
using McNemar’s test (23). Primary analyses were conducted
which assessed the change in healthcare professionals’
Table 1 Questions used to assess the degree of smoking cessation advice given by healthcare professionals at baseline, week 7 and week 52 orpremature discontinuation
Do you determine the smoking status of your patients regularly?†Do you inform patients that smoking is harmful?‡Do you advise patients to quit smoking?‡Do you provide patients with behavioural counselling during a quit attempt?†Do you think the fact that you smoke influences the advice you give to patients regarding smoking?†Do you agree that your personal experience with smoking-cessation products influences your prescribing practices?§
*Post baseline questions 1, 2, 3 and 4 changed to ‘Will you …; †Yes/no; ‡Always/only if they ask/only if they are symptomatic/never/other;§Strongly agree/agree/neutral/disagree/strongly disagree.
ª 2005 Blackwell Publishing Ltd Int J Clin Pract, April 2005, 59, 4, 447–452
CHANGING HEALTH PROFESSIONALS’ ATTITUDES TO SMOKING
responses from baseline to week 52. A sensitivity analysis was
determine the smoking status of their patients (Figure 1A),
also conducted, which considered the latest questions to be
inform their patients that smoking was harmful (Figure 1B)
completed for each subject, whether this was at week 7, week
and would advise their patients to quit smoking (Figure 1C).
52 or at the withdrawal visit (if the subject withdrew from the
There was an increase in the percentage of healthcare profes-
study at an early stage). Subjects withdrawing or not complet-
sionals who provided behavioural counselling while attempt-
ing the questions at week 52 may not have had similar change
ing to quit smoking (Figure 1D). Additionally, when asked
compared with those subjects who completed the questions at
whether or not their personal experience with smoking-
week 52. Therefore, to assess bias, a secondary analysis was
cessation products influenced their prescribing practice, a
performed, with the responses to the last questions carried
greater percentage of participants either agreed or strongly
agreed than they did at baseline (Figure 1E).
Shift Analysis by Health Professionals’ Involvement in aSmoking-Cessation Programme
For the shift analysis, patient responses at baseline and week
A total of 690 health professionals were enrolled in the study,
of which 687 formed the ITT population. Of these, 517 and
At week 52, there was a significantly positive shift in the
170 subjects were randomised to receive either bupropion SR
number of subjects answering that they would determine the
or placebo, respectively. A total of 568 patients remained in
smoking status of their patients [based on 468 subjects who
the study at the end of week 7 (83%) and 501 at the end of
completed, 14.1% increase; 95% confidence interval (CI)
week 52 (73%). Following an audit, the data from one centre
9.1–19.1%; p < 0.001] compared with baseline. A similar
in the study were excluded from the efficacy analyses, as the
result was observed when the responses for last questions
validity and integrity of the data from this centre (20 subjects)
completed were carried forward (586 subjects, 13.0%
could not be confirmed. Therefore, the data are presented
increase; 95% CI 8.6–17.4%; p < 0.001).
based upon the results from 25 (n 5 501, bupropion SR;
A total of 471 health professionals answered the question
n 5 166, placebo) of the 26 centres. The treatment groups
‘Do you inform patients that smoking is harmful?’ at baseline
were comparable in terms of age, gender, occupation and
and week 52. There was a positive shift in subjects answering
‘always’ to this question (19.5% increase; 95% CI 14.8–24.3%),
Overall, a comparison of responses at baseline vs. those
which was highly significant (p < 0.001). The sensitivity
from the end of treatment (week 7) and the end of the
analysis provided similar results (585 subjects, 18.1% increase;
study (week 52) indicated a positive shift towards a more
proactive approach to smoking cessation. This shift appeared
Based upon those subjects (n 5 469) who answered the
unrelated to treatment received or smoking status.
question ‘Do you advise patients to quit smoking?’, therewas a significant positive shift in the number of health profes-
Health Professionals’ Response to Individual Questions
sionals who answered ‘always’ at the end of the study com-
Responses from subjects at the specified time points during
pared with baseline (22.4% increase; 95% CI 17.5–27.3%;
the study are displayed graphically in Figure 1A–E. All data
p < 0.001). Results from the sensitivity analysis including the
described in this section are comparisons of the baseline
last questions completed were also comparable (586 subjects,
responses with those at the end of treatment (week 7) and
21.1% increase; 95% CI 16.8–25.5%; p < 0.001).
the end of the study (week 52) (population of completers). A
A total of 445 subjects responded to the question ‘Do you
greater percentage of health professionals said that they would
provide patients with behavioural counselling during a quit
Table 2 Demographics of study participants
*Bupropion SR, n 5 501; placebo, n 5 165; †Pack year history 5 [(number of years smoking) · (number of cigarettes/day)]/20.
ª 2005 Blackwell Publishing Ltd Int J Clin Pract, April 2005, 59, 4, 447–452
CHANGING HEALTH PROFESSIONALS’ ATTITUDES TO SMOKING
attempt?’ at baseline and at week 52, and a 36.6% increase
(95% CI 31.7–41.5%; p < 0.001) in those answering ‘yes’
was recorded. The sensitivity analysis provided similar results
(558 subjects, 36.2% increase; 95% CI 31.8–40.6%; p < 0.001).
From the health professionals (n 5 234) who responded to
the question ‘Does your experience with smoking cessation
products influence your prescribing practices?’, a significant
shift was observed in the number of subjects who answered
‘yes’ at baseline to those who gave this answer at week 52
(12.0% increase; 95% CI 4.8–19.1%; p 5 0.002). Results
from the sensitivity analysis including the last questions com-
pleted were also comparable (280 subjects, 11.8% increase;
Across all questions, the results from the sensitivity analyses
were highly consistent with those from the primary analyses.
While many health professionals agree that intervention in
smoking cessation is an intrinsic part of their role, many
physicians and nurses in either a primary or secondary care
setting do not provide smoking cessation advice to their
patients (14). However, patients who are heavy smokers,
suffering from ill health or have multiple physician visits are
more likely to be advised to quit smoking (14). Based on the
results of our study, only 36% of health professionals at
baseline always advised patients to quit smoking. This figure
is within the range reported in other studies. Twenty-one
percent of smokers in Finland who had visited a physician
during the previous year received advice to stop (24), 34% of
smokers in Switzerland recalled being advised to stop (15),
and 50% of general practitioners sampled in England and
Wales advised all smokers to quit at most or all consultations
Such moderate rates of smoking cessation advice from
physicians may reflect the lack of understanding that health
professionals have of their important role in smoking cessa-
tion and how they can become actively involved. It is clear
that when physicians engage their patients, almost 40% of
smokers make some form of attempt to quit in response to a
physician’s advice (26,27) and this can lead to moderate quit
rates of up to 10% (28–30). However, for health profes-
sionals, many barriers exist to the routine provision of smok-
ing cessation advice to smokers, including the pressures of
time during consultation and pessimism about their own
efficacy, skills and expertise at counselling and their patients’
Figure 1 Responses given by health professionals at baseline, week 7
capacity to change lifestyle behaviour (31).
and week 52 (population of completers) to the following questions
It is not surprising that these healthcare professionals
regarding smoking and smoking cessation: (A) Do you determine the
became more proactive in providing smoking cessation
smoking status of your patients regularly? (B) Do you inform patientsthat smoking is harmful? (C) Do you advise patients to quit smoking?
advice. Although this study did not train the participants in
(D) Do you provide patients with behavioural counselling during a quit
the provision of smoking-cessation support and treatment,
attempt? (E) Do you agree that your personal experience with smoking-
these professionals were probably influenced by the education
cessation products influences your prescribing practice?
they received as a smoking cessation study participant. The
ª 2005 Blackwell Publishing Ltd Int J Clin Pract, April 2005, 59, 4, 447–452
CHANGING HEALTH PROFESSIONALS’ ATTITUDES TO SMOKING
provision of education or even simple advice to physicians
smoking-cessation advice, irrespective of study treatment or
and nurses on how to engage patients who are smokers about
final study outcome (i.e. abstainers or non-abstainers). The
cessation can help health professionals overcome some of the
significant and positive shift among these health professionals
obstacles hindering counselling by health professionals.
led many subjects to indicate that, in future, they would
Equally, building a rapport with their patients who are smokers
determine the smoking status of their patients regularly,
and assessing their patients’ motivation and confidence to
inform them that smoking is harmful and advise them to
quit, can be key elements in the smoking-cessation process
quit, whilst also providing counselling during a quit attempt.
(31). Unfortunately, physicians tend to feel more comfortable
The adoption of a more proactive approach to smoking
with providing assistance when smokers request it, for
cessation by health professionals is particularly relevant
instance when suffering from smoking-related diseases (32).
when it has been shown that during a recent 12-month
It is also perceived by physicians to be more in line with what
period, over 60% of people attempting to stop smoking in
the patient expects from their visit to a physician (25).
the UK did not seek any help or advice, and of those who did,
How health professionals view smoking is equally import-
only 7% contacted a physician or other health professional
ant – is it perceived as a lifestyle or a strong health risk, i.e. do
physicians and nurses attempt to educate their patients about
In conclusion, the present study emphasises the need for
this risk and provide advice on how to eliminate it? It has
effective education of health professionals on appropriate
been suggested that health professionals may see unsolicited
strategies to engage their staff and patients in smoking cessa-
lifestyle advice, such as that relating to smoking cessation, as
tion. It also highlights the value of involving physicians and
incompatible with their caring role and as a risk to the
nurses who smoke in smoking-cessation programmes. Such
physician–patient relationship (4). Furthermore, some phys-
involvement should be widely considered in national
icians may fear alienating patients who are not receptive to
smoking-control programmes for both health professionals
such advice (33). In addition, health professionals who smoke
themselves may not be as effective in counselling theirpatients compared with their nonsmoking colleagues, and
consequently, their own smoking behaviour may impactnegatively upon that of their patients (10,12).
We gratefully acknowledge the assistance of the Principal
Counselling of smokers by health professionals is recom-
Investigators in the ZybanÒ Healthcare Professionals Study
mended by numerous smoking cessation guidelines (19,34);
yet, when questioned almost 50% of smokers had not
Austria: Aigner K, Irsigler K and Schinko H. Estonia:
received such counselling during a previous 12-month period
Sepper R. Finland: Puska P. Greece: Siafakas N, Roussos C
when they had previously visited a physician in a primary or
and Patakas D. Germany: Batra A, Boelcskei P, Moecke H
secondary healthcare setting (14). A similar percentage of
and Schmidt L. Israel: Kramer M. Italy: Dezio A and
health professionals in the present study had also failed to
Giuntini C. Latvia: Raibarts J. Lithuania: Blaziene A. Poland:
provide patient counselling prior to study entry. Although
Gorecka D and Sadowski Z. Spain: Alvarez Sala J, Barrueco M,
physicians and nurses are advised to help patients quit smok-
Izquierdo J, Jiminez Ruiz C and Rubio M. Switzerland:
ing, counselling/motivational support is only a component of
the cessation process, albeit an important component.
Furthermore, despite the comprehensive pharmacotherapeu-
St Bartholomew’s and the Royal London School of Medicine
tic strategies currently available for helping smokers to quit
and Dentistry, London, UK, who developed the motivational
and their recommendation for use by health guidelines
support protocol used in this study.
(19,20), many physicians remain unaware of the beneficialrole pharmacological treatments can play in assisting smokers
to stop (25). Indeed, the combined use of behavioural therapyand pharmacotherapy can dramatically improve the patient’s
1 Peto R. Smoking and death: The past 40 years and the next 40.
chance of quitting smoking as highlighted by the sustained
1-year abstinence rates of approximately 20% among patients,
2 American Cancer Society. Cancer Facts and Figures Washington,
after treatment with bupropion SR (17,35).
3 Doll R, Peto R, Wheatley K et al. Mortality in relation to smoking: 40
The findings from the present study are promising and
years’ observations on male British doctors. BMJ 1994; 309: 901–11.
highlight the willingness of health professionals to help their
4 Fowler G. Smoking cessation: The role of general practitioners,
smoking patients, when they become more personally
nurses and pharmacists. In: Bollinger CT, Fagerstrom KO, eds.
involved with cessation. The involvement of health profes-
The Tobacco Epidemic, Vol. 28 Basel: Karger, 1997; 165–77.
sionals in a smoking-cessation programme had a beneficial
5 39th World Health Assembly, 1986. Tobacco or Health: Resolution
effect on the proactivity of physicians and nurses in providing
WHA 39.14 Geneva: World Health Organization, 1990.
ª 2005 Blackwell Publishing Ltd Int J Clin Pract, April 2005, 59, 4, 447–452
CHANGING HEALTH PROFESSIONALS’ ATTITUDES TO SMOKING
6 Josseran L, King G, Velter A et al. Smoking behaviour and
23 Altman DG. Practical Statistics for Medical Research London:
opinions of French general practitioners. J Natl Med Assoc
24 Healakorpi S, Patja K, Pra¨tta¨la¨ R, Uutela A. Health behaviour
7 McKenna H, Slater P, McCance T et al. Qualified nurses’
and health among Finnish adult population. Spring 2001. Pub-
smoking prevalence: Their reasons for smoking and desire to
lications of the National Public Health Institute B 16/2001.
quit. J Adv Nurs 2001; 35: 769–75.
http://www.ktl.fi/publications//b16.pdf.
8 Muzi G, dell’Omo M, Crespi E et al. Smoking in the workplace.
25 McEwen A, West R. Smoking cessation activities by general
Study at a hospital in central Italy. Med Lav 2001; 92: 54–60.
practitioners and practice nurses. Tob Control 2001; 10: 27–32.
9 Nardini S, Bertolli R, Rastelli V, Donner CF. The influence of
26 Russell MA, Wilson C, Taylor C et al. Effect of general practi-
personal tobacco smoking on the clinical practice of Italian chest
tioners’ advice against smoking. BMJ 1979; 2: 231–5.
physicians. Eur Respir J 1998; 12: 1450–3.
27 Kreuter MW, Cheda SG, Bull FC. How does physician advice
10 Olive KE, Ballard JA. Attitudes of patients toward smoking by
influence patient behaviour? Evidence of a priming effect. Arch
health professionals. Public Health Rep 1992; 107: 335–9.
11 Chapman S. Doctors who smoke. BMJ 1995; 311: 142–3.
28 Cummings SR, Coates TJ, Richard RJ et al. Training physicians
12 Ohida T, Sakurai H, Mochizuki Y et al. Smoking prevalence and
in counselling about smoking cessation: A randomised trial of
attitudes toward smoking among Japanese physicians. JAMA
the Quit for Life program. Ann Intern Med 1989; 110: 640–7.
29 Strecher VJ, O’Malley MS, Villagra VG et al. Can residents be
13 Grossman DW, Knox JJ, Nash C, Jimenez JG. Smoking atti-
trained to counsel patients about quitting smoking? Results from
tudes of Costa Rican physicians and opportunities for interven-
a randomised trial. J Gen Intern Med 1991; 6: 9–17.
tion. Bull World Health Organ 1999; 77: 315–22.
30 Westmaas JL, Nath V, Brandon TH. Contemporary smoking
14 Doescher MP, Saver BG. Physician’s advice to quit smoking.
cessation. Cancer Control 2000; 7: 56–62.
31 Rollnick S, Butler CC, Stott N. Helping smokers make deci-
15 Eckert T, Junker C. Motivation for smoking cessation: What
sions: The enhancement of brief intervention for general medical
role do doctors play? Swiss Med Wkly 2001; 131: 521–6.
practice. Patient Educ Couns 1997; 31: 191–203.
16 Davis RM. When doctors smoke. Tob Control 1993; 2: 187–8.
32 Coleman T, Murphy E, Cheater F. Factors influencing discus-
17 Hurt RD, Sachs DP, Glover ED et al. A comparison of
sion of smoking between general practitioners and patients who
sustained-release bupropion and placebo for smoking cessation.
smoke: A qualitative study. Br J Gen Pract 2000; 50: 207–10.
33 McCarty MC, Zander KM, Hennrikus DJ, Lando HA. Barriers
18 Tashkin DP, Kanner R, Bailey W et al. Smoking cessation in
among nurses to providing smoking cessation advice to hospital-
patients with chronic obstructive pulmonary disease: A double-
ized smokers. Am J Health Promot 2001; 16: 85–7.
blind, placebo-controlled, randomized trial. Lancet 2001; 357:
34 Raw M, McNeill A, West R. Smoking cessation guidelines for
health professionals – A guide to effective smoking cessation
19 Fiore MC, Bailey WC, Cohen SJ et al. Treating Tobacco Use and
interventions for the health care system. Thorax 1998; 53:
Dependence. Clinical Practice Guideline Rockville, MD: U.S.
Department of Health and Human Services. Public Health
35 Jorenby DE, Leischow SJ, Nides MA et al. A controlled trial of
sustained-release bupropion, a nicotine patch, or both for smok-
20 West R, McNeill A, Raw M. Smoking cessation guidelines for
ing cessation. N Engl J Med 1999; 340: 685–91.
health professionals: An update. Thorax 2000; 55: 987–99.
36 Office of National Statistics. Smoking related behaviour and
21 Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking
cessation. Cochrane Database Syst Rev 2000; 4: CD000031.
22 Zellweger JP, Boelcskei P, Carrozzi L et al. Bupropion SR for smoking
cessation in healthcare professionals. Am J Health Behav (in press).
Paper received July 2004, accepted December 2004
ª 2005 Blackwell Publishing Ltd Int J Clin Pract, April 2005, 59, 4, 447–452
DR. JERRY B. EMTAGE M.B. B.S. (HONS) F.R.C.S (C) DIPLOMAT OF THE AMERICAN BOARD OF UROLOGY “CHELFORD”, GEORGE WASHINGTON HOUSE Red Yeast Extract Reduces Major Coronary Events in Large, Randomized Clinical Trial CME/CE News Author: Michael O'Riordan June 16, 2008 — A large, randomized clinical trial with the partially purified extract of Chinese red yeast rice has shown that
ALFA Musicorum Convivium e La serva Padrona ALFA MC presenta l'ensemble Eptafon ne "La Serva Padrona", intermezzo buffo di G.B. Pergolesi con: Serpina Fausta Ciceroni, Uberto Alessio Magnaguagno, Vespone Ariele Vincenti, M.o concertatore Alessandro di Petrillo e la piccola orchestra da camera Eptafon. La Serva Padrona, ossia la storia infinita del primato di quella metà del ciel